Chlordiazepoxide

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Chlordiazepoxide

Examples of brand names: Librium [USA]

ATC code: N05BA02

Main use (for orientation): Anxiety; alcohol withdrawal

Documented research summary

Several older animal experiments show THC/chlordiazepoxide effects on catalepsy or cannabinoid blood concentrations; other models show CBD-related reduction in potency. No demonstrated clinical interaction dose rule; preparation/model dependence remains crucial.

Uncertainties and limitations

Does not establish safety for less-studied cannabinoids or untested formulations/doses.

Do not infer clinical dosage from preclinical effects or enzyme hypotheses.

Separately recorded findings

4 separately recorded findings. Each statement applies to its documented study context.

THC – laboratory and animal studies

Finding ID: B0345

Type of result: Preclinical evidence

Observation: Chlordiazepoxide enhanced THC-induced catalepsy.

Mechanism: Preclinical combination, not a clinically isolated mechanism

Study type: Rat and mouse experiments

Context studied: Rats: chlordiazepoxide 10 mg/kg subcutaneously; mice: chlordiazepoxide 5.5–30 mg/kg subcutaneously and THC 5–20 mg/kg intraperitoneally at 34°C.

Clinical interpretation: Do not extrapolate to humans or individual use.

Limitations and uncertainties: Abstracts only; GABA hypothesis, no quantification of human sedation.

Original sources for this finding: Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids. [C_PR_1649415]; Delta-9-tetrahydrocannabinol-induced catalepsy in mice is enhanced by pretreatment with flurazepam or chlordiazepoxide. [C_PR_2839791]

THC – laboratory and animal studies

Finding ID: B0346

Type of result: Preclinical evidence

Observation: Cannabinoid blood concentrations increased with concomitant chlordiazepoxide; no synergy in the reproductive endpoints investigated.

Mechanism: Preclinical combination, not a clinically isolated mechanism

Study type: Pregnant mice

Context studied: Gestational day 6 until birth; lower fetal weight with both substances.

Clinical interpretation: Do not extrapolate to humans or individual use.

Limitations and uncertainties: Abstract-based; do not confuse with safety in human pregnancy.

Original sources for this finding: Effects of delta-9-tetrahydrocannabinol, chlordiazepoxide (Librium), and their combination on pregnancy and offspring in mice [correction of rats]. [C_PR_2856545]

CBD – laboratory and animal studies

Finding ID: B0347

Type of result: Preclinical evidence

Observation: CBD reduced the anticonvulsant potency of chlordiazepoxide.

Mechanism: Preclinical combination, not a clinically isolated mechanism

Study type: Rat experiment

Context studied: Oral substances, electroshock/audiogenic tests.

Clinical interpretation: Do not extrapolate to humans or individual use.

Limitations and uncertainties: Abstract only, not a clinical antagonism rule.

Original sources for this finding: Cannabidiol--antiepileptic drug comparisons and interactions in experimentally induced seizures in rats. [C_PR_850145]

THC – laboratory and animal studies

Finding ID: B0348

Type of result: Preclinical evidence

Observation: Chlordiazepoxide 5 mg/kg inhibited THC-induced conditioned gaping.

Mechanism: Preclinical combination, not a clinically isolated mechanism

Study type: Male rats

Context studied: Model of stress-associated THC-induced nausea.

Clinical interpretation: Do not extrapolate to humans or individual use.

Limitations and uncertainties: Preclinical modulation of a THC effect, not a clinical cannabinoid-hyperemesis treatment recommendation.

Original sources for this finding: Role of the stress response and the endocannabinoid system in Δ9-tetrahydrocannabinol (THC)-induced nausea. [BMED32399633]

References and access status

[C_LABEL_D0071_UK] Librium 5 mg Capsules – SmPC

Original source / bibliographic reference

Authors: Viatris Products Limited

Year: 2025

Source type: UK SmPC

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[BMED32399633] Role of the stress response and the endocannabinoid system in Δ9-tetrahydrocannabinol (THC)-induced nausea.

Original source / bibliographic reference

Authors: DeVuono MV, La Caprara O, Sullivan MT, Bath A, Petrie GN, Limebeer CL, Rock EM, Hill MN, Parker LA.

Year: 2020

Source type: Publication; title and abstract reviewed

DOI: 10.1007/s00213-020-05529-5

PMID: 32399633

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

[C_PR_2856545] Effects of delta-9-tetrahydrocannabinol, chlordiazepoxide (Librium), and their combination on pregnancy and offspring in mice [correction of rats].

Original source / bibliographic reference

Authors: Abel EL, Tan SE.

Year: 1987

Source type: Primary source, abstract read

DOI: 10.1016/0890-6238(87)90069-4

PMID: 2856545

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[C_PR_1649415] Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids.

Original source / bibliographic reference

Authors: Pertwee RG, Wickens AP.

Year: 1991

Source type: Primary source, abstract read

DOI: 10.1016/0028-3908(91)90150-a

PMID: 1649415

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[C_PR_2839791] Delta-9-tetrahydrocannabinol-induced catalepsy in mice is enhanced by pretreatment with flurazepam or chlordiazepoxide.

Original source / bibliographic reference

Authors: Pertwee RG, Greentree SG.

Year: 1988

Source type: Primary source, abstract read

DOI: 10.1016/0028-3908(88)90130-x

PMID: 2839791

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[C_PR_850145] Cannabidiol--antiepileptic drug comparisons and interactions in experimentally induced seizures in rats.

Original source / bibliographic reference

Authors: Consroe P, Wolkin A.

Year: 1977

Source type: Primary source, abstract read

DOI: 10.1016/s0022-3565(25)30824-4

PMID: 850145

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility